Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GANX

Gain Therapeutics Inc

Apr 18 • 04:00PM ET

3.15

Dollar change -0.03
Percentage change -0.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	16.40%	Shs Outstand	16.21M	Perf Week	-6.25%
Market Cap	51.09M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	1.06%	Shs Float	13.56M	Perf Month	-25.88%
Income	-22.27M	PEG	-	EPS next Q	-0.32	Inst Own	9.53%	Short Float	1.02%	Perf Quarter	-6.25%
Sales	0.06M	P/S	851.55	EPS this Y	29.16%	Inst Trans	9.32%	Short Ratio	0.87	Perf Half Y	-5.26%
Book/sh	0.78	P/B	4.06	EPS next Y	6.44%	ROA	-104.28%	Short Interest	0.14M	Perf Year	-35.45%
Cash/sh	1.04	P/C	3.04	EPS next 5Y	-	ROE	-141.57%	52W Range	2.00 - 6.19	Perf YTD	-3.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-79.01%	ROI	-167.97%	52W High	-49.11%	Beta	0.49
Dividend TTM	-	Quick Ratio	3.59	Sales past 5Y	93.18%	Gross Margin	-51.47%	52W Low	57.50%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	3.59	EPS Y/Y TTM	-15.79%	Oper. Margin	-40328.26%	RSI (14)	30.06	Volatility	7.81% 9.22%
Employees	32	Debt/Eq	0.08	Sales Y/Y TTM	-60.62%	Profit Margin	-40354.33%	Recom	1.00	Target Price	8.75
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	25.90%	Payout	-	Rel Volume	0.49	Prev Close	3.18
Sales Surprise	-100.00%	EPS Surprise	7.05%	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	159.49K	Price	3.15
SMA20	-13.20%	SMA50	-25.19%	SMA200	-11.49%	Trades		Volume	78,261	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-21	Initiated	Oppenheimer	Outperform	$30
Apr-12-21	Initiated	BTIG Research	Buy	$30

Apr-17-24 09:55AM	Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher (Zacks)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
09:35AM	Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) (Zacks)
Apr-08-24 09:25AM	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer (GlobeNewswire)
Apr-02-24 05:40PM	Insiders Are Buying These 5 Penny Stocks (Insider Monkey)
07:01PM	Loading…
Apr-01-24 07:01PM	Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX) (GuruFocus.com)
09:25AM	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Mar-26-24 01:53PM	GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:00AM	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update (GlobeNewswire)
Mar-15-24 02:30PM	Gain Therapeutics to Present at Public Ventures Discovery Day (GlobeNewswire)
Mar-05-24 09:45AM	EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease (Benzinga)
08:00AM	Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease (GlobeNewswire)
Feb-27-24 02:00PM	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire)
Feb-14-24 12:29PM	Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight (GlobeNewswire)
Feb-06-24 09:56AM	UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease (GlobeNewswire)
08:00AM	Loading…
08:00AM	Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease (GlobeNewswire)
Jan-31-24 08:00AM	Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update (GlobeNewswire)
Jan-24-24 12:00PM	Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-02-24 08:00AM	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium 2024 (GlobeNewswire) +11.03%
Dec-14-23 09:55AM	Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now (Zacks) -5.22%
Dec-04-23 08:00AM	Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research (GlobeNewswire) +6.82%
Dec-01-23 08:00AM	Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model (GlobeNewswire)
Nov-29-23 08:00AM	Gain Therapeutics to Participate in AI Driven Drug Discovery Summit (GlobeNewswire)
Nov-24-23 01:01PM	Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Nov-22-23 11:58AM	Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock (Zacks)
Nov-21-23 08:54AM	Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants (GlobeNewswire) -23.90%
Nov-20-23 04:03PM	Gain Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-14-23 07:00AM	Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-04-23 08:45AM	Why Is Gain Therapeutics (GANX) Stock Moving Today? (InvestorPlace) -6.62%
07:00AM	Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire)
04:05PM	Loading…
Sep-25-23 04:05PM	Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-20-23 04:05PM	Gain Therapeutics to Present at the Cambridge Healthtech Institutes 2nd Annual Neurodegeneration Targets Conference (GlobeNewswire)
Sep-12-23 09:25AM	Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia (GlobeNewswire)
Aug-29-23 08:57AM	Gain Therapeutics Achieves Remarkable Breakthrough in Parkinsons Disease Research (News Direct)
Aug-28-23 07:00AM	Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinsons Disease Model (GlobeNewswire)
Aug-10-23 08:25AM	Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.33%
07:00AM	Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-07-23 07:00AM	Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinsons Disease and Movement Disorders® (GlobeNewswire)
Jul-31-23 08:00AM	Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-01-23 08:00AM	Gain Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-23 08:09AM	Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 09:15AM	Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-08-23 10:00AM	Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-03-23 09:15AM	Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinsons Disease (GlobeNewswire)
Apr-12-23 04:30PM	Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer (GlobeNewswire)
Mar-29-23 08:52AM	Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting (GlobeNewswire)
Mar-23-23 04:05PM	Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Mar-22-23 08:30AM	Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders (GlobeNewswire)
Mar-21-23 08:00AM	Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program (GlobeNewswire) +5.31%
Mar-09-23 08:00AM	Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) -5.08%
Feb-27-23 08:00AM	Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium (GlobeNewswire)
Feb-02-23 08:00AM	Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-12-23 04:05PM	Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference (GlobeNewswire)
Nov-10-22 05:15PM	Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:02PM	Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Sep-26-22 11:59AM	Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program (Benzinga)
08:00AM	Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinsons Disease Patient-Derived Dopaminergic Neurons (GlobeNewswire)
Sep-20-22 07:30AM	Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer (GlobeNewswire)
Sep-19-22 08:00AM	Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinsons Disease (GlobeNewswire) -7.39%
Sep-08-22 08:00AM	Gain Therapeutics to Present Data at Upcoming Medical Meetings (GlobeNewswire)
Sep-06-22 08:00AM	Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-08-22 09:15AM	Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Aug-04-22 08:00AM	Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference (GlobeNewswire)
Aug-03-22 10:00AM	Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jun-02-22 08:00AM	Gain Therapeutics to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 08:00AM	Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-16-22 05:55PM	Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
May-11-22 09:30AM	Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium (GlobeNewswire) -13.17%
May-06-22 08:00AM	Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinsons Disease at XXVII IAPRD World Congress (GlobeNewswire) -11.37%
May-03-22 08:31AM	Cloopen Announced Formation of Independent Special Committee for Internal Investigation (PR Newswire) +11.80%
May-02-22 03:00PM	Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-22 05:19PM	Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference (GlobeNewswire) -8.12%
Apr-12-22 01:00PM	Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinsons Disease at the 2022 Synuclein Meeting (GlobeNewswire) -7.40%
Mar-29-22 08:00AM	Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference (GlobeNewswire)
Mar-24-22 08:00AM	Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update (GlobeNewswire)
Mar-15-22 08:00AM	Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinsons and Alzheimers Disease at the AD/PD 2022 Conference (GlobeNewswire)
Mar-01-22 08:00AM	Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences (GlobeNewswire) +5.15%
Feb-08-22 08:00AM	Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022 (GlobeNewswire) -6.81%
Feb-04-22 12:06PM	Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day (GlobeNewswire)
Jan-31-22 04:05PM	Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day (GlobeNewswire)
Jan-18-22 08:00AM	Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences (GlobeNewswire)
Jan-06-22 04:05PM	Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference (GlobeNewswire)
Dec-28-21 04:05PM	Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.43%
Dec-16-21 06:57AM	What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own? (Simply Wall St.)
Dec-07-21 08:00AM	Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update (GlobeNewswire) +8.80%
Dec-01-21 04:07PM	Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit (GlobeNewswire)
Nov-12-21 09:52AM	2 Strong Buy Stocks Under $10 With Triple-Digit Upside (TipRanks) +10.29%
07:00AM	Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Nov-11-21 11:00AM	Gain Therapeutics Presents Parkinsons Disease Preclinical Study Results at Society for Neuroscience Annual Meeting (GlobeNewswire)
Nov-10-21 11:00AM	Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinsons Disease and Gaucher Disease (GlobeNewswire) +9.48%
Nov-04-21 04:05PM	Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Oct-28-21 08:00AM	Gain Therapeutics to Present at Upcoming Medical Conferences (GlobeNewswire)
Oct-26-21 08:00AM	Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB) (GlobeNewswire)
Oct-19-21 08:00AM	Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer (GlobeNewswire)
Oct-12-21 10:07AM	Gain Therapeutics' SEE-Tx Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding (Benzinga)
Sep-23-21 08:00AM	Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference (GlobeNewswire)

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riley Jeffrey Scott	Director	Mar 28 '24	Buy	3.86	30,000	115,770	30,000	Apr 01 04:01 PM
Alder Matthias	Chief Executive Officer	Dec 21 '23	Sale	2.46	206	507	5,286	Dec 22 04:17 PM
Alder Matthias	Chief Executive Officer	Dec 07 '23	Sale	2.50	1,820	4,550	4,855	Dec 14 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GANX

Gain Therapeutics Inc

Upgrade your FINVIZ experience